MOTS-c Dosage: What the Research Shows and What It Does Not
MOTS-c has the most interesting origin story in the peptide world: it is encoded inside mitochondrial DNA, not the nuclear genome. That is genuinely novel science. It is also not a dosing schedule.
There is no established MOTS-c dose. It is a 16-amino-acid mitochondrial-derived peptide identified in 2015, and the research that made it famous is mouse work showing improved insulin sensitivity and resistance to diet-induced obesity, alongside human observational studies measuring naturally circulating levels rather than administering the peptide. No published human dose-finding or efficacy trial exists, so figures circulating in protocols — commonly described as 5–10 mg per week split across injections — come from vendors and user practice, not research. MOTS-c is not an approved medicine anywhere, and metabolic modulators of this kind fall foul of anti-doping rules.
MOTS-c amounts by source of the number
| Use case | Amount reported in sources | What to know |
|---|---|---|
| Published human dose-finding trials | None | No completed published trial has administered MOTS-c to humans and reported dose-response results. Source |
| Commonly circulated community protocol | Often described as 5–10 mg per week, split across injections, for four weeks | Vendor and forum practice. No pharmacokinetic data in humans support any of these figures. Source |
| Mouse studies | Expressed in mg per kg of body weight, given by intraperitoneal injection | A route and species that cannot be converted into a human subcutaneous protocol with any confidence. Source |
| Human observational research | Measures naturally circulating MOTS-c in blood | Studies have examined how endogenous levels relate to exercise, age and metabolic disease — not what happens when it is injected. Source |
Figures are amounts reported in the cited sources, not a personal recommendation. Your own amount depends on your health, medicines and blood work.
What MOTS-c is
MOTS-c stands for mitochondrial open reading frame of the 12S rRNA type-c. It is a short peptide encoded within mitochondrial DNA, described in 2015, and it belongs to a small family of mitochondrial-derived peptides that also includes humanin. Its identification mattered because it showed that mitochondria encode signalling molecules that act on the rest of the cell and on distant tissues.
The proposed mechanism involves the folate–methionine cycle and AMPK activation, which is the same broad signalling territory as exercise and metformin. That is precisely why it attracted attention as a potential exercise mimetic.
Interesting biology and a usable drug are separated by a decade of trials. MOTS-c is currently on the near side of that gap.
- A 16-amino-acid peptide encoded in mitochondrial DNA
- Described in 2015; part of the mitochondrial-derived peptide family
- Proposed to act via AMPK and the folate–methionine cycle
- Attracted attention as a possible exercise-mimetic mechanism
The mouse findings that drive the marketing
In mice, administered MOTS-c has been reported to improve insulin sensitivity, resist high-fat-diet-induced obesity, and improve physical performance in older animals. Those are striking results, and they are the source of essentially every claim made in MOTS-c sales copy.
Two limits should be attached to them. First, mouse metabolic models are notoriously generous: many compounds that reverse diet-induced obesity in rodents do nothing measurable in humans. Second, the doses were given by intraperitoneal injection at milligram-per-kilogram levels, a route not used in human practice.
None of that makes the mouse work wrong. It makes it a hypothesis about humans rather than a finding about humans.
- Improved insulin sensitivity and reduced diet-induced obesity in mice
- Reported performance improvements in older mice
- Intraperitoneal route, mg/kg doses — not transferable
- Rodent metabolic benefit frequently fails to replicate in people
What human research exists
Human MOTS-c research has largely measured the peptide people already produce. Studies have looked at how circulating levels change with acute exercise, how they differ with age, and how they associate with insulin resistance, obesity and cardiometabolic disease. Some report that exercise raises MOTS-c in skeletal muscle and plasma.
That body of work supports the idea that MOTS-c is part of the metabolic response to exercise. It does not show that injecting it reproduces the benefits of exercise, any more than measuring higher endorphins after a run shows that injecting endorphins makes you fitter.
The absence of registered interventional trials is the practical bottom line: nobody has established a safe dose, a duration, a monitoring plan, or an outcome that improves in humans.
- Observational studies of naturally circulating MOTS-c
- Associations with exercise, ageing and insulin resistance
- Association is not the same as benefit from administration
- No registered interventional dose-finding trial
Practical risks of the current market
MOTS-c is sold as research-use-only material by suppliers with no obligation to verify identity, purity or sterility. For a peptide with no human safety data, that compounds two unknowns: what the molecule does, and whether the vial contains it.
For athletes, the anti-doping position is unforgiving. Substances that alter metabolic signalling — including agents marketed as exercise mimetics — sit in prohibited categories, and anything without regulatory approval for human therapeutic use is captured by WADA's S0 class regardless of what it is called on the label.
For everyone else, the reasonable framing is that MOTS-c is a research topic worth following rather than a product with a dose. If a trial is eventually published, it will supply the number this page cannot.
- Unregulated supply with no identity or sterility assurance
- No human safety data to interpret a reaction against
- Captured by WADA S0 as a non-approved substance
- Reasonable position: follow the research, do not guess a protocol
What the published studies found
Each entry below links straight to the paper or the health authority page so you can read the original rather than take our word for it.
- Identification and metabolic characterisation of MOTS-c
Laboratory and mouse studies
Described a mitochondrial-derived peptide that activates AMPK signalling and, when administered to mice, improved insulin sensitivity and reduced diet-induced obesity.
- MOTS-c and exercise in humans
Observational human studies measuring endogenous peptide levels
Reported that MOTS-c levels in skeletal muscle and plasma change with acute exercise and differ across age and metabolic status; the peptide was measured, not administered.
- Registered MOTS-c interventional studies
Clinical trial registry search
No completed registered interventional trial establishes a human dose, duration or efficacy outcome for administered MOTS-c.
Side effects reported in the literature
Commonly reported
- Injection-site reactions reported anecdotally
- Flushing or fatigue reported anecdotally
- No systematically collected adverse-event data exist
Serious, seek medical advice
- The human safety profile is entirely unknown — no controlled trials
- Metabolic signalling effects have not been characterised in people with diabetes
- Sterility and contamination risk from unregulated research-grade vials
- No data on interaction with existing metabolic medication
Summarised from ClinicalTrials.gov — absence of completed interventional trials. Report anything unexpected to your own doctor or pharmacist.
Interactions to check with a pharmacist
| Medicine or condition | What sources report |
|---|---|
| Metformin and other AMPK-adjacent metabolic drugs | The proposed mechanism overlaps; no interaction has been studied, and combined metabolic effects in humans are unknown. Source |
| Insulin and glucose-lowering therapy | Any agent proposed to improve insulin sensitivity could in principle affect glucose control; this has not been measured in people. Source |
| Anti-doping programmes | Non-approved substances are prohibited at all times under WADA S0, and metabolic modulators are separately restricted. Source |
This is not a complete interaction list. Check your own medicines with a pharmacist before combining anything.
This page is reference material, not medical advice. Supplements interact with prescription medicines and with each other. Talk to a doctor or pharmacist before starting anything, especially if you are pregnant, breastfeeding, managing a health condition or taking prescription medicine.
Frequently asked questions
What is the correct MOTS-c dose?
No correct dose exists. There is no published human dose-finding trial. Protocols quoting figures such as 5–10 mg per week are repeating vendor and forum practice, not research.
What is MOTS-c?
It is a 16-amino-acid peptide encoded inside mitochondrial DNA, described in 2015. It is thought to signal through AMPK and the folate–methionine cycle, which is the same broad pathway influenced by exercise and metformin.
Has MOTS-c been tested in humans?
Not as an administered drug in a completed dose-finding trial. Human studies have measured naturally circulating MOTS-c and how it relates to exercise, age and metabolic health.
Does MOTS-c work like exercise?
That is the hypothesis, based on mouse studies and on the observation that exercise raises endogenous levels. Showing that a molecule rises with exercise is not the same as showing that injecting it produces the effects of exercise.
Is MOTS-c safe?
Unknown. There is no controlled human safety dataset, no characterised adverse-event profile, and no interaction data with metabolic medication. The supply chain adds a separate sterility and identity risk.
Is MOTS-c legal?
It is not an approved medicine in any major jurisdiction and is sold labelled for research use only. For athletes it falls under WADA's prohibition of non-approved substances at all times.
How does MOTS-c differ from other peptides sold for metabolism?
Most metabolic peptides sold online are analogues of hormones with known receptors and, in some cases, approved medicines behind them. MOTS-c is a genuinely novel mitochondrial-derived peptide whose therapeutic development has not yet reached human trials.
Keep reading
Sources
Track your dose in DoseRoutine
Log what you actually take, get reminders at the right time and check interactions against everything else in your stack.
Sign up free →